Jing Wang1, Li Ma2, Jianghong Guo1, Yanfeng Xi1, Enwei Xu1. 1. Department of Pathology, Shanxi Tumor Hospital, No. 3, Kaixuan Street, Xinghualing District, Taiyuan City, Shanxi Province, China. 2. Department of Hematology, Shanxi Tumor Hospital, No. 3, Kaixuan Street, Xinghualing District, Taiyuan City, Shanxi Province, China.
Abstract
OBJECTIVE: The aim of this study is to evaluate the clinicopathological features and the treatment of the Burkitt-like lymphoma with 11q aberration. METHODS: We reported two patients with Burkitt-like lymphoma with 11q aberration: a 56-year-old man with AIDS (case 1) and a 37-year-old woman (case 2) without AIDS. The biopsy of cervical lymph nodes showed Burkitt-like morphologic and immunophenotypic features. But both of them lack MYC rearrangement and carry an 11q-arm aberration with proximal gains and/or telomeric losses. The diagnosis was confirmed by pathological morphology, immunohistochemistry, and fluorescence in situ hybridization. RESULT: After a cycle of R-CTOEP (rituximab, cyclophosphamide, pirarubicin, vincristine, and prednisone) chemotherapy, case 1 refused to chemotherapy and radiotherapy and was followed up for 34 months without recurrence and new focus. Case 2 received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for two cycles and achieved PR (partial response). Then, the patient in case 2 received EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) for three cycles, and the right cervical mass disappeared. She achieved complete response and was followed up for 16 months without recurrence and new focus. CONCLUSION: Burkitt-like lymphoma with 11q abnormalities resembles Burkitt lymphoma morphologically but lacks MYC rearrangement and may have a better prognosis.
OBJECTIVE: The aim of this study is to evaluate the clinicopathological features and the treatment of the Burkitt-like lymphoma with 11q aberration. METHODS: We reported two patients with Burkitt-like lymphoma with 11q aberration: a 56-year-old man with AIDS (case 1) and a 37-year-old woman (case 2) without AIDS. The biopsy of cervical lymph nodes showed Burkitt-like morphologic and immunophenotypic features. But both of them lack MYC rearrangement and carry an 11q-arm aberration with proximal gains and/or telomeric losses. The diagnosis was confirmed by pathological morphology, immunohistochemistry, and fluorescence in situ hybridization. RESULT: After a cycle of R-CTOEP (rituximab, cyclophosphamide, pirarubicin, vincristine, and prednisone) chemotherapy, case 1 refused to chemotherapy and radiotherapy and was followed up for 34 months without recurrence and new focus. Case 2 received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) for two cycles and achieved PR (partial response). Then, the patient in case 2 received EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) for three cycles, and the right cervical mass disappeared. She achieved complete response and was followed up for 16 months without recurrence and new focus. CONCLUSION: Burkitt-like lymphoma with 11q abnormalities resembles Burkitt lymphoma morphologically but lacks MYC rearrangement and may have a better prognosis.
Authors: Barbara Pienkowska-Grela; Grzegorz Rymkiewicz; Beata Grygalewicz; Renata Woroniecka; Paulina Krawczyk; Katarzyna Czyz-Domanska; Jan Walewski Journal: Med Oncol Date: 2010-07-27 Impact factor: 3.064
Authors: Itziar Salaverria; Idoia Martin-Guerrero; Rabea Wagener; Markus Kreuz; Christian W Kohler; Julia Richter; Barbara Pienkowska-Grela; Patrick Adam; Birgit Burkhardt; Alexander Claviez; Christine Damm-Welk; Hans G Drexler; Michael Hummel; Elaine S Jaffe; Ralf Küppers; Christine Lefebvre; Jasmin Lisfeld; Markus Löffler; Roderick A F Macleod; Inga Nagel; Ilske Oschlies; Maciej Rosolowski; Robert B Russell; Grzegorz Rymkiewicz; Detlev Schindler; Matthias Schlesner; René Scholtysik; Carsten Schwaenen; Rainer Spang; Monika Szczepanowski; Lorenz Trümper; Inga Vater; Swen Wessendorf; Wolfram Klapper; Reiner Siebert Journal: Blood Date: 2014-01-07 Impact factor: 22.113
Authors: Julia Richter; Matthias Schlesner; Steve Hoffmann; Markus Kreuz; Ellen Leich; Birgit Burkhardt; Maciej Rosolowski; Ole Ammerpohl; Rabea Wagener; Stephan H Bernhart; Dido Lenze; Monika Szczepanowski; Maren Paulsen; Simone Lipinski; Robert B Russell; Sabine Adam-Klages; Gordana Apic; Alexander Claviez; Dirk Hasenclever; Volker Hovestadt; Nadine Hornig; Jan O Korbel; Dieter Kube; David Langenberger; Chris Lawerenz; Jasmin Lisfeld; Katharina Meyer; Simone Picelli; Jordan Pischimarov; Bernhard Radlwimmer; Tobias Rausch; Marius Rohde; Markus Schilhabel; René Scholtysik; Rainer Spang; Heiko Trautmann; Thorsten Zenz; Arndt Borkhardt; Hans G Drexler; Peter Möller; Roderick A F MacLeod; Christiane Pott; Stefan Schreiber; Lorenz Trümper; Markus Loeffler; Peter F Stadler; Peter Lichter; Roland Eils; Ralf Küppers; Michael Hummel; Wolfram Klapper; Philip Rosenstiel; Andreas Rosenwald; Benedikt Brors; Reiner Siebert Journal: Nat Genet Date: 2012-11-11 Impact factor: 38.330
Authors: Alyssa Bouska; Timothy W McKeithan; Karen E Deffenbacher; Cynthia Lachel; George W Wright; Javeed Iqbal; Lynette M Smith; Weiwei Zhang; Can Kucuk; Andrea Rinaldi; Francesco Bertoni; Jude Fitzgibbon; Kai Fu; Dennis D Weisenburger; Timothy C Greiner; Bhavana J Dave; Randy D Gascoyne; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Jan Delabie; Elaine S Jaffe; Rita M Braziel; Joseph M Connors; Louis M Staudt; Wing-Chung Chan Journal: Blood Date: 2013-09-13 Impact factor: 22.113
Authors: Blanca Gonzalez-Farre; Joan Enric Ramis-Zaldivar; Julia Salmeron-Villalobos; Olga Balagué; Verónica Celis; Jaime Verdu-Amoros; Ferran Nadeu; Constantino Sábado; Antonio Ferrández; Marta Garrido; Federico García-Bragado; María Dolores de la Maya; José Manuel Vagace; Carlos Manuel Panizo; Itziar Astigarraga; Mara Andrés; Elaine S Jaffe; Elias Campo; Itziar Salaverria Journal: Haematologica Date: 2019-02-07 Impact factor: 9.941